



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING	DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/673,958	08/13/2	2001	Masayoshi Nanba	2519US0P	8993
23115	7590 09/15/2004			EXAMINER	
TAKEDA PHARMACEUTICALS NORTH AMERICA, INC				WHITEMAN, BRIAN A	
	INTELLECTUAL PROPERTY DEPARTMENT 475 HALF DAY ROAD				PAPER NUMBER
SUITE 500 LINCOLNSHIRE, IL 60069				1635	
				DATE MAILED: 09/15/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/673,958	NANBA ET AL.				
,	Examiner	Art Unit				
	Brian Whiteman	1635				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
THE REPLY FILED 01 September 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
a) The period for reply expires 3 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
 1. ☐ A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal. 2. ☒ The proposed amendment(s) will not be entered because: 						
(a) ☑ they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) ☐ they raise the issue of new matter (see Note below);						
(c) ☐ they are not deemèd to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) They present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE: <u>See Continuation Sheet</u> .		·				
3. Applicant's reply has overcome the following rejection(s):						
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See Continuation Sheet</u> .						
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
7. ☐ For purposes of Appeal, the proposed amendment(s) a) ☐ will not be entered or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed: None.						
Claim(s) objected to: None.						
Claim(s) rejected: <u>1-5</u> .						
Claim(s) withdrawn from consideration: None.						
8. \boxtimes The drawing correction filed on <u>01 September 2004</u> is a) \boxtimes approved or b) \square disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
10.⊠ Other: See Continuation Sheet						

Continuation of 2. NOTE: Proposed amendment to claim 1 would require further search and consideration because the amendment does not require the cell to express the enzymes CYP1A1, CYP1A2, and CYP3A.

Continuation of 5. does NOT place the application in condition for allowance because: The argument is moot because the arugment is based on an amendment that was not entered.

Continuation of 10. Other: The abstract is objected to because the abstract contains legal phraseology. See the term "said" on lines 3 and 18 of the abstract filed on 4/19/04.

A deposit has been made under the Budapest Treaty. However, Applicants have not provided a statement by affidavit or declaration, or by a statement by an attorney of record over his or her signature and registration number showing that: all restriction upon availability to the public will be irrevocably removed upon granting of the patent.

SCOTT D. PRIEBE, PH.D PRIMARY EXAMINER

Scott D. Priche